pamidronate has been researched along with Disease Exacerbation in 23 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study evaluated whether additional palliative benefits could be derived from the second-line use of the more potent bisphosphonate zoledronic acid in metastatic breast cancer patients with either progressive bone metastases or skeletal-related events (SRE), despite first-line therapy with either pamidronate or clodronate." | 9.12 | Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. ( Clemons, MJ; Cole, DE; Dranitsaris, G; Ooi, WS; Pritchard, KI; Sukovic, T; Trudeau, M; Verma, S; Wong, BY; Yogendran, G, 2006) |
| "A total of 295 patients with lytic bone metastases from breast cancer were randomized to receive chemotherapy or chemotherapy plus pamidronate (Aredia) 45 mg intravenously every 3 weeks." | 9.07 | Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomized, multicenter phase III trial. ( Calabresi, F; Conte, PF; Ford, JM; Giannessi, PG; Koliren, L; Latreille, J; Mauriac, L, 1994) |
| "This study evaluated whether additional palliative benefits could be derived from the second-line use of the more potent bisphosphonate zoledronic acid in metastatic breast cancer patients with either progressive bone metastases or skeletal-related events (SRE), despite first-line therapy with either pamidronate or clodronate." | 5.12 | Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. ( Clemons, MJ; Cole, DE; Dranitsaris, G; Ooi, WS; Pritchard, KI; Sukovic, T; Trudeau, M; Verma, S; Wong, BY; Yogendran, G, 2006) |
| "Twelve patients with smouldering or indolent multiple myeloma (MM) received 12 courses of intravenous pamidronate as a single agent to evaluate both the antitumour and bone metabolism effects." | 5.10 | Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect. ( Bladé, J; Fernández-Calvo, J; García-Sanz, R; González, M; Hernández, J; Martín, A; Mateo, G; Orfao, A; San Miguel, JF; Suquía, B, 2002) |
| "A total of 295 patients with lytic bone metastases from breast cancer were randomized to receive chemotherapy or chemotherapy plus pamidronate (Aredia) 45 mg intravenously every 3 weeks." | 5.07 | Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomized, multicenter phase III trial. ( Calabresi, F; Conte, PF; Ford, JM; Giannessi, PG; Koliren, L; Latreille, J; Mauriac, L, 1994) |
| " We report here on a child with McCune-Albright syndrome (FD in addition to hyperfunctioning endocrinopathies and skin hyperpigmentation) treated with cyclical intravenous infusions of pamidronate in which conventional radiography, contact microradiography, histology, and backscattered electron image analysis demonstrated that zebra lines formed only where bone was normal, were arrested at the boundary between FD-unaffected and FD-affected bone where bone is sclerotic, and were absent within the undermineralized FD bone." | 3.85 | Bisphosphonate-induced zebra lines in fibrous dysplasia of bone: histo-radiographic correlation in a case of McCune-Albright syndrome. ( Boyde, A; Corsi, A; Ippolito, E; Riminucci, M; Robey, PG, 2017) |
| "To examine outcomes of pamidronate treatment on fibrous dysplasia of bone in three children with McCune-Albright syndrome (MAS)." | 3.73 | Pamidronate treatment of polyostotic fibrous dysplasia: failure to prevent expansion of dysplastic lesions during childhood. ( Chan, B; Zacharin, M, 2006) |
| "Smoldering multiple myeloma (SMM) is usually followed expectantly without therapy." | 2.73 | Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease. ( Alsayed, Y; Anaissie, E; Barlogie, B; Crowley, J; Epstein, J; Hoering, A; Hollmig, K; Jenkins, B; Kumar, NS; Petty, N; Pineda-Roman, M; Shaughnessy, JD; Srivastava, G; Szymonifka, J; van Rhee, F; Yaccoby, S; Zeldis, JB, 2008) |
| "Hypocalcemia was treated with calcium and vitamin D3 supplements." | 2.44 | [Zoledronate-associated end stage renal failure and hypocalcaemia]. ( Bodmer, M; Kummer, O; Ramazzina, C; Rätz Bravo, AE; Zysset Aschmann, Y, 2007) |
| " Intravenous pamidronate is efficacious and has long been available, but its use is hindered by an impractical recommended dosing regimen of 30 mg IV over 4 h for three consecutive days." | 2.44 | A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg. ( Abelson, A, 2008) |
| "Pamidronate appears to be an effective treatment in children with CNO unresponsive to NSAIDs." | 1.40 | Efficacy of pamidronate therapy in children with chronic non-bacterial osteitis: disease activity assessment by whole body magnetic resonance imaging. ( Finn, A; Ramanan, AV; Roderick, M; Shah, R, 2014) |
| "Targeting bone resorption might therefore provide an approach to the treatment of high bone resorbing forms of OA." | 1.36 | Inhibition of bone resorption blunts osteoarthritis in mice with high bone remodelling. ( Cohen-Solal, ME; Ea, HK; Funck-Brentano, T; Geoffroy, V; Hannouche, D; Kadri, A; Lin, H; Lioté, F; Marty, C, 2010) |
| "Cutaneous melanoma is one of the highly malignant human tumours, due to its tendency to generate early metastases and its resistance to classical chemotherapy." | 1.32 | Nitrogen-containing bisphosphonates inhibit cell cycle progression in human melanoma cells. ( Forsea, AM; Geilen, CC; Müller, C; Orfanos, CE; Riebeling, C, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.35) | 18.2507 |
| 2000's | 13 (56.52) | 29.6817 |
| 2010's | 8 (34.78) | 24.3611 |
| 2020's | 1 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Bhat, CS | 1 |
| Chopra, M | 1 |
| Andronikou, S | 1 |
| Paul, S | 1 |
| Wener-Fligner, Z | 1 |
| Merkoulovitch, A | 1 |
| Holjar-Erlic, I | 1 |
| Menegotto, F | 1 |
| Simpson, E | 1 |
| Grier, D | 1 |
| Ramanan, AV | 2 |
| Corsi, A | 1 |
| Ippolito, E | 1 |
| Robey, PG | 1 |
| Riminucci, M | 1 |
| Boyde, A | 1 |
| Andreasen, CM | 1 |
| Jurik, AG | 1 |
| Glerup, MB | 1 |
| Høst, C | 1 |
| Mahler, BT | 1 |
| Hauge, EM | 1 |
| Herlin, T | 1 |
| Hahn, NM | 1 |
| Yiannoutsos, CT | 1 |
| Kirkpatrick, K | 1 |
| Sharma, J | 1 |
| Sweeney, CJ | 1 |
| Roderick, M | 1 |
| Shah, R | 1 |
| Finn, A | 1 |
| Rayson, D | 1 |
| Barlogie, B | 1 |
| van Rhee, F | 1 |
| Shaughnessy, JD | 1 |
| Epstein, J | 1 |
| Yaccoby, S | 1 |
| Pineda-Roman, M | 1 |
| Hollmig, K | 1 |
| Alsayed, Y | 1 |
| Hoering, A | 1 |
| Szymonifka, J | 1 |
| Anaissie, E | 1 |
| Petty, N | 1 |
| Kumar, NS | 1 |
| Srivastava, G | 1 |
| Jenkins, B | 1 |
| Crowley, J | 1 |
| Zeldis, JB | 1 |
| Kadri, A | 1 |
| Funck-Brentano, T | 1 |
| Lin, H | 1 |
| Ea, HK | 1 |
| Hannouche, D | 1 |
| Marty, C | 1 |
| Lioté, F | 1 |
| Geoffroy, V | 1 |
| Cohen-Solal, ME | 1 |
| D'Arena, G | 1 |
| Gobbi, PG | 1 |
| Broglia, C | 1 |
| Sacchi, S | 1 |
| Quarta, G | 1 |
| Baldini, L | 1 |
| Iannitto, E | 1 |
| Falcone, A | 2 |
| Guariglia, R | 1 |
| Pietrantuono, G | 1 |
| Villani, O | 1 |
| Martorelli, MC | 1 |
| Mansueto, G | 1 |
| Sanpaolo, G | 2 |
| Cascavilla, N | 2 |
| Musto, P | 2 |
| Watters, AL | 1 |
| Hansen, HJ | 1 |
| Williams, T | 1 |
| Chou, JF | 1 |
| Riedel, E | 1 |
| Halpern, J | 1 |
| Tunick, S | 1 |
| Bohle, G | 1 |
| Huryn, JM | 1 |
| Estilo, CL | 1 |
| Bodenizza, C | 1 |
| Melillo, L | 1 |
| Scalzulli, PR | 1 |
| Dell'Olio, M | 1 |
| La Sala, A | 1 |
| Mantuano, S | 1 |
| Nobile, M | 1 |
| Carella, AM | 1 |
| Healey, JH | 1 |
| Shannon, F | 1 |
| Boland, P | 1 |
| DiResta, GR | 1 |
| Forsea, AM | 1 |
| Müller, C | 1 |
| Riebeling, C | 1 |
| Orfanos, CE | 1 |
| Geilen, CC | 1 |
| Liauw, W | 1 |
| Segelov, E | 1 |
| Lih, A | 1 |
| Dunleavy, R | 1 |
| Links, M | 1 |
| Ward, R | 1 |
| Chan, B | 1 |
| Zacharin, M | 1 |
| Hou, JW | 1 |
| Yang, M | 1 |
| Burton, DW | 1 |
| Geller, J | 1 |
| Hillegonds, DJ | 1 |
| Hastings, RH | 1 |
| Deftos, LJ | 1 |
| Hoffman, RM | 1 |
| Bhansali, A | 1 |
| Singh, R | 1 |
| Sriraam, M | 1 |
| Bhadada, S | 1 |
| Clemons, MJ | 1 |
| Dranitsaris, G | 1 |
| Ooi, WS | 1 |
| Yogendran, G | 1 |
| Sukovic, T | 1 |
| Wong, BY | 1 |
| Verma, S | 1 |
| Pritchard, KI | 1 |
| Trudeau, M | 1 |
| Cole, DE | 1 |
| Ramazzina, C | 1 |
| Zysset Aschmann, Y | 1 |
| Kummer, O | 1 |
| Rätz Bravo, AE | 1 |
| Bodmer, M | 1 |
| Abelson, A | 1 |
| Conte, PF | 1 |
| Giannessi, PG | 1 |
| Latreille, J | 1 |
| Mauriac, L | 1 |
| Koliren, L | 1 |
| Calabresi, F | 1 |
| Ford, JM | 1 |
| Martín, A | 1 |
| García-Sanz, R | 1 |
| Hernández, J | 1 |
| Bladé, J | 1 |
| Suquía, B | 1 |
| Fernández-Calvo, J | 1 |
| González, M | 1 |
| Mateo, G | 1 |
| Orfao, A | 1 |
| San Miguel, JF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41[NCT00216060] | Phase 3 | 63 participants (Actual) | Interventional | 2003-10-31 | Terminated (stopped due to Terminated due to low accrual) | ||
| UARK 98-036, A Phase II Trial of Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide in Patients With Smoldering/Indolent Myeloma[NCT00083382] | Phase 2 | 83 participants (Actual) | Interventional | 1998-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of participants experiencing a SRE(skeletal-related event) or death occurred, cumulative from each arm ( a daily oral dose of 30 mg risedronate, or placebo) (NCT00216060)
Timeframe: 36 months
| Intervention | participants (Number) |
|---|---|
| Risedronate Arm | 11 |
| Placebo Arm | 13 |
(NCT00216060)
Timeframe: 36 months
| Intervention | percentage of participants (Number) |
|---|---|
| Risedronate Arm | 50 |
| Placebo Arm | 29 |
(NCT00216060)
Timeframe: 36 months
| Intervention | percentage of participants (Number) |
|---|---|
| Risedronate | 72.5 |
| Placebo | 71.5 |
"Urine total DPD median in response to treatment on both study arms at week 24. compare median from baseline and week 24.~Deoxypyridinoline (DPD) is measured in hydrolyzed urine samples using high-performance liquid chromatography technique. After extraction of the cross-links and elimination of the urine impurities by a Bio-Rad SPE cartridge (Bio-Rad Laboratories, Hercules, CA), total DPD is eluted from reverse-phase high-performance liquid chromatography by ion pair chromatography with isocratic elution.~The compounds are detected as a result of their natural fluorescence with a fluorescence detector" (NCT00216060)
Timeframe: 24 weeks
| Intervention | nmol/mmol creatinine (Median) | |
|---|---|---|
| week 24 | baseline | |
| Placebo Arm | 12.62 | 10.12 |
| Risedronate Arm | 6.91 | 8.83 |
Serum BAP median changes between baseline and week 24. The Ostase assays are performed with an access immunoassay system, which is an assay of serum samples that provides a quantitative measurement of bone alkaline phosphatase (BAP). A mouse monoclonal antibody specific to BAP is added to a re-action vessel with paramagnetic particles coated with goat antimouse polyclonalantibody.Calibrators,controls,andsamplescontainingBAP are added to the coated particles and bind to the anti-BAP monoclonal antibody. After the formation of a solid phase/capture antibody/BAP complex, separation in a magnetic field and washing remove materials not bound to the solid phase. A chemiluminescent substrate, LumiPhos 530, is added to the reaction vessel, and light generated by the reaction is measured with a luminometer. The light production is directly proportional to the concentration of BAP in the sample. The amount of analyte in thesample is determined from a stored multipoint calibration curve (NCT00216060)
Timeframe: 24 week
| Intervention | ng/mL (Median) | |
|---|---|---|
| 24 week | baseline | |
| Placebo Arm | 13.16 | 19.50 |
| Risedronate Arm | 9.5 | 20.95 |
Serum Osteocalcin (OC) medians between baseline and 24 weeks areperformed with the Elecsys 2010 automated analyzer, which uses an electrochemiluminescence immunoassay technique for the in vitro quantitative determination of serum total osteocalcin in humanserum. The assay uses a sandwich test principle in which afirst biotinylated monoclonal antibody recognizing N-MID osteocalcin and a second monoclonal antibody against N-MID osteocalcin labeled with ruthenium are incubated with 20mL of serum. After a first incubation, streptavidin-coated microparticles are added for a second incubation, and the complex becomes bound to the solid phase by interaction of biotin and streptavidin.These microparticles are then magnetically captured onto the surface of an electrode. Application of a voltage on this electrode induces chemiluminescent emission, which is measured by a photomultiplierand compared with a calibration curve that is generated in aninstrument-specific manner by 2-point calibration. (NCT00216060)
Timeframe: 24 week
| Intervention | ug/L (Median) | |
|---|---|---|
| at 24 week | baseline | |
| Placebo Arm | 27.35 | 18.24 |
| Risedronate Arm | 11.88 | 20.08 |
"Urine N-telopeptide (NTX) median changes between baseline and week 24. The assays are performed with the NTx Reagent Pack kit from Ortho-Clinical Diagnostics (Ortho-Clinical Diagnostics/Johnson & Johnson, Amersham, UK), which is a kit designed for the quantitative determination of N-terminal telopeptide (NTx) in human urine on the automated Vitros Immunodiagnostic System ECi (Ortho-Clinical Diagnostics/Johnson & Johnson, Amersham, UK). A competitive immunoassay technique is used. This depends on competition between NTx present in the sample and a synthetic NTx peptide coated on the wells for binding by a horseradish peroxidase (HRP)-labeled antibody conjugate (mouse monoclonal anti-NTx). The conjugate is captured by the peptide coated on the wells; unbound materials are removed by washing.~The bound HRP conjugate is measured by a luminescent reaction." (NCT00216060)
Timeframe: 24 week
| Intervention | nmol BCE/mmol creatinine (Median) | |
|---|---|---|
| at 24 week | baseline | |
| Placebo Arm | 62.95 | 48.08 |
| Risedronate Arm | 20.63 | 41.33 |
"Best response to study treatment as defined by protocol-specific response criteria:~Complete Response (CR) = absence of urine and serum M-components by immunofixation; bone marrow should be adequately cellular (>20%) with <1% monoclonal plasma cells by DNA-clg flow cytometry; serum calcium level must be normal; no new bone lesions nor enlargement of existing lesions; Normalization of serum concentrations of normal immunoglobulins is not required for CR. Partial Response (PR) = Reduction by > 75% in serum myeloma protein production; Decrease in monoclonal marrow plasmacytosis to <5%; Decrease in Bence-Jones proteinuria by >90%; No new lytic bone lesions or soft tissue plasmacytoma.~Treatment Failures/Progressive Disease (PD) = Such patients do not fulfill the above criteria and/or have new lytic lesions (but not compression fractures), hypercalcemia, or other new manifestations of disease." (NCT00083382)
Timeframe: 2 years
| Intervention | participants (Number) | ||
|---|---|---|---|
| Treatment Failure/Progressive Disease | Partial Response | Complete Response | |
| Thalidomide + Bisphosphonate | 56 | 17 | 10 |
3 reviews available for pamidronate and Disease Exacerbation
| Article | Year |
|---|---|
PMMA to stabilize bone and deliver antineoplastic and antiresorptive agents.
Topics: Antineoplastic Agents; Bone Cements; Diphosphonates; Disease Progression; Doxorubicin; Drug Delivery | 2003 |
[Zoledronate-associated end stage renal failure and hypocalcaemia].
Topics: Acute Kidney Injury; Adverse Drug Reaction Reporting Systems; Age Factors; Aged; Aged, 80 and over; | 2007 |
A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Disease Progression; Etidronic Acid; Humans; | 2008 |
7 trials available for pamidronate and Disease Exacerbation
| Article | Year |
|---|---|
Failure to suppress markers of bone turnover on first-line hormone therapy for metastatic prostate cancer is associated with shorter time to skeletal-related event.
Topics: Aged; Alkaline Phosphatase; Amino Acids; Androgen Antagonists; Antibodies, Monoclonal, Humanized; Bi | 2014 |
Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Diphosphonates; Disease Progression; Di | 2008 |
Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Diseases; Diphosphonates; Dis | 2011 |
Pamidronate reduces skeletal events but does not improve progression-free survival in early-stage untreated myeloma: results of a randomized trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2003 |
Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
Topics: Adult; Aged; Aged, 80 and over; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Br | 2006 |
Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomized, multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Disease Progre | 1994 |
Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect.
Topics: Aged; Bone Remodeling; Diphosphonates; Disease Progression; Female; Follow-Up Studies; Humans; Infus | 2002 |
13 other studies available for pamidronate and Disease Exacerbation
| Article | Year |
|---|---|
Artificial intelligence for interpretation of segments of whole body MRI in CNO: pilot study comparing radiologists versus machine learning algorithm.
Topics: Adolescent; Artificial Intelligence; Bone Density Conservation Agents; Chronic Disease; Disease Prog | 2020 |
Bisphosphonate-induced zebra lines in fibrous dysplasia of bone: histo-radiographic correlation in a case of McCune-Albright syndrome.
Topics: Adolescent; Diphosphonates; Disease Progression; Female; Femur; Fibrous Dysplasia, Polyostotic; Huma | 2017 |
Response to Early-onset Pamidronate Treatment in Chronic Nonbacterial Osteomyelitis: A Retrospective Single-center Study.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Bone Density Conservation Agents; Child; Denmar | 2019 |
Efficacy of pamidronate therapy in children with chronic non-bacterial osteitis: disease activity assessment by whole body magnetic resonance imaging.
Topics: Adolescent; Anti-Inflammatory Agents; Child; Child, Preschool; Chronic Disease; Diphosphonates; Dise | 2014 |
White Knuckling.
Topics: Adaptation, Psychological; Aged; Antineoplastic Agents; Attitude to Death; Bone Neoplasms; Breast Ne | 2016 |
Inhibition of bone resorption blunts osteoarthritis in mice with high bone remodelling.
Topics: ADAM Proteins; Animals; Arthritis, Experimental; Bone Density Conservation Agents; Bone Remodeling; | 2010 |
Intravenous bisphosphonate-related osteonecrosis of the jaw: long-term follow-up of 109 patients.
Topics: Adult; Aged; Aged, 80 and over; Bisphosphonate-Associated Osteonecrosis of the Jaw; Chi-Square Distr | 2013 |
Nitrogen-containing bisphosphonates inhibit cell cycle progression in human melanoma cells.
Topics: Antimetabolites; Antineoplastic Agents; Cell Cycle; Clodronic Acid; Diphosphonates; Disease Progress | 2004 |
Off-trial evaluation of bisphosphonates in patients with metastatic breast cancer.
Topics: Aged; Bone Diseases; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Dis | 2005 |
Pamidronate treatment of polyostotic fibrous dysplasia: failure to prevent expansion of dysplastic lesions during childhood.
Topics: Adolescent; Bone and Bones; Bone Density Conservation Agents; Child; Child, Preschool; Diphosphonate | 2006 |
Progressive osseous heteroplasia controlled by intravenous administration of pamidronate.
Topics: Adult; Bone Density Conservation Agents; Child, Preschool; Chromogranins; Diphosphonates; Disease Pr | 2006 |
The bisphosphonate olpadronate inhibits skeletal prostate cancer progression in a green fluorescent protein nude mouse model.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Calcium; Cell Line, Tumor; Diphosphonates | 2006 |
Pachydermoperiostitis and bisphosphonates.
Topics: Adolescent; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Disease Progression; | 2006 |